KPAX 002

Drug Profile

KPAX 002

Alternative Names: KPAX002

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator K-PAX Pharmaceuticals
  • Class Amino acids; Phenylacetates; Piperidines
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic fatigue syndrome; Cognition disorders

Most Recent Events

  • 24 Apr 2018 Efficacy and safety data from the phase II Synergy trial in Chronic fatigue syndrome released by K-PAX Pharmaceuticals
  • 21 Sep 2015 K-PAX Pharmaceuticals has patent protection for KPAX 002 in USA
  • 01 Jan 2015 Phase-II clinical trials in Cognition disorders in USA (PO) (NCT02357030)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top